Akorn-Strides jv enters purchase agreement with Pfizer for ANDAs Akorn.

We would like to thank our joint venture partner, Strides, for helping build value inside our joint venture which has led to a mutually helpful strategic outcome.’.. Akorn-Strides jv enters purchase agreement with Pfizer for ANDAs Akorn, Inc. , a distinct segment generic pharmaceutical organization, today reported that its Akorn-Strides LLC joint venture has entered right into a purchase contract with Pfizer Inc. To sell 16 Abbreviated New Medication Approvals and 6 filed ANDAs. For its portion, Akorn, Inc. Will receive $35 million in money. Akorn-Strides LLC will continue steadily to produce and distribute the authorized items until April 30, 2011.Acticoat Flex can be an antimicrobial barrier dressing made to comply with body contours and invite for flexible movement for injuries that require sustained antimicrobial activity. ‘We are pleased to support Smith Nephew in the European release of Acticoat Flex,’ stated David B. Holtz, Interim President and CEO, and Chief Financial Officer of NUCRYST. ‘The enhanced conformability of Flex will today be available to European clinicians to simplifying the dressing of wounds on difficult-to-protect articulating regions such as for example knee or elbow joints while also offering advanced antimicrobial protection.’ The CE Mark Qualification for Acticoat Flex was received by Smith Nephew the other day following the July 510 clearance in the usa and market acceptance in Canada late last year.